NCT06376175

Completed

Task Atlas: Study to Develop a Task Atlas of Brain Recruitme...

Lumos Labs, Inc.Source

Compare

Other study identifiers

Sponsor study identifier

LL-016

Study Type

observational

Actual enrollment (reported)

37

Locations

1 country

Sites

1

Timeline

Study Start

April 24, 2024

Actual (reported)

Primary Completion

December 15, 2024

Actual (reported)

Study Completion

January 15, 2025

Actual (reported)

Brief Summary

Healthy volunteers ages 25-40 from the general US population who meet the eligibility criteria and are enrolled will (a) play Lumosity games at least 20 times each in under 60 days and (b) then complete one session of task-based functional magnetic resonance imaging (fMRI) while playing Lumosity games.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 37 participants
Study completion date: January 15, 2025
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
April 3, 2024
Actual (reported)
First Posted
April 19, 2024
Actual (reported)
Study Start
April 24, 2024
Actual (reported)
Primary Completion
December 15, 2024
Actual (reported)
Study Completion
January 15, 2025
Actual (reported)

Last Updated: January 31, 2025
Status Verified: January 2025
Last Update Submitted: January 29, 2025

Conditions

Healthy Adults

Keywords

cognitionfMRI

Outcome Measures

Primary Outcomes (8)

BOLD response during gameplay
Whole-brain blood oxygen level-dependent (BOLD) response during gameplay
Day 60
Responder rates
Percentage of participants who show A) BOLD response by brain region during gameplay, B) Between-network connectivity, based on BOLD responses, during gameplay, C) Within-network connectivity, based on BOLD responses, during gameplay
Day 60
Structural MRI volumetrics: Volume
Volume at rest
Day 60
Structural MRI volumetrics: Cortical thickness
Cortical thickness measured in millimeters
Day 60
Structural MRI volumetrics: Brain-Predicted Age Difference
Brain-Predicted Age Difference at rest
Day 60

Eligibility Criteria

Age25 Years - 40 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

Healthy adults age 25-40

You may qualify if:

Subjects 25-40 years of age.

Sponsors & Collaborators

Lumos Labs, Inc.
Industrylead

Study Sites (1)

UC Davis Imaging Research Center (IRC)

Sacramento, California, 95817, United States

Study Officials

Kevin Madore, PhD
Lumos Labs, Inc.
PRINCIPAL INVESTIGATOR

Enrollment

37 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 3, 2024

First Posted

April 19, 2024

Study Start

April 24, 2024

Actual (reported)

NCT05930197

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

Phase 1Completed

NCT06815991

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

Phase 1Recruiting

NCT05918679

The Brain Processes Underlying Speech Motor Learning and Speech Production

Not ApplicableRecruiting

NCT05924152

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Phase 1Completed

NCT06929455

Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines

Not ApplicableRecruiting

NCT06656338

Phase 2 Seattle Dietary Biomarkers Development Center

Not ApplicableCompleted

Behavior response: Game score

Score on game after completion of gameplay

Day 60

BAMS-7 (Brief Attention and Mood Scale of 7 Items)

Subject-reported BAMS-7 (Brief Attention and Mood Scale of 7 Items) including the Attention subscale, Mood subscale, and Total, measured post-imaging

Day 60

VGPQ (Video Game Playing Questionnaire)

Subject-reported VGPQ (Video Game Playing Questionnaire) including non-video game playing (NVGP) and video game playing (VGP)

Day 60

Ability to understand and speak English, follow written and verbal instructions (English), and give informed consent (English), as assessed by the PI or project manager.

Ability to comply with all the testing and study requirements, including the ability to independently complete daily, online Lumosity games on a reliable, internet-connected device.

Geographical location within 100 miles of the study imaging center.

You may not qualify if:

Current, controlled (requiring treatment) or uncontrolled psychiatric diagnosis, including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention- deficit/hyperactivity disorder, or other symptomatic manifestations that in the opinion of the PI may confound study data/assessments.
Current, controlled (requiring treatment) or uncontrolled neurological diagnosis, including but not limited to Alzheimer's Disease, other dementias, mild cognitive impairment, Huntington's Disease, Parkinson's Disease, multiple sclerosis, stroke, epilepsy, aphasia, or other condition that in the opinion of the PI may confound study data/assessments.
Any other medical condition in the last 90 days that in the opinion of the PI may confound study data/assessments.
Has been under the care of a caretaker or has not been living independently in the last 90 days.
In the last three years has used online brain training programs (e.g., BrainHQ, Lumosity, Peak) for more than two weeks continuously.
Known sensitivity (such as headaches, dizziness, nausea) to bright, stimulating video displays.
History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy.
Visual acuity that cannot be corrected that prevents or negatively impacts computer activity.
Pregnancy, or strong likelihood of pregnancy.
Left-handed or ambidextrous.
Unwillingness or inability to comply with imaging safety protocols. Inability includes but is not limited to metal implants or exposure to shrapnel.
Any other condition that in the opinion of the PI may confound study data.

Contact the study team to confirm eligibility.

Primary Completion

December 15, 2024

Actual (reported)

Study Completion

January 15, 2025

Actual (reported)

Last Updated

January 31, 2025

Record last verified: 2025-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06376175
Data provider: ClinicalTrials.gov
Source updated: 2025-01-31
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:25:55 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (8)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations